Novanta Inc. (NASDAQ:NOVT – Get Free Report) CEO Matthijs Glastra sold 7,500 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $179.70, for a total transaction of $1,347,750.00. Following the transaction, the chief executive officer now owns 56,382 shares in the company, valued at approximately $10,131,845.40. This trade represents a 11.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Novanta Stock Down 0.3 %
NOVT opened at $169.71 on Friday. Novanta Inc. has a twelve month low of $136.36 and a twelve month high of $187.12. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.81 and a current ratio of 2.79. The business has a 50 day moving average price of $174.07 and a 200 day moving average price of $170.48. The firm has a market cap of $6.10 billion, a P/E ratio of 101.65 and a beta of 1.29.
Novanta (NASDAQ:NOVT – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The technology company reported $0.85 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.85. The business had revenue of $244.40 million during the quarter, compared to the consensus estimate of $242.33 million. Novanta had a net margin of 6.52% and a return on equity of 15.20%. Novanta’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.85 EPS. Research analysts forecast that Novanta Inc. will post 3.03 EPS for the current year.
Institutional Trading of Novanta
Analyst Ratings Changes
Separately, Robert W. Baird lowered their target price on shares of Novanta from $175.00 to $169.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th.
View Our Latest Report on Novanta
About Novanta
Novanta Inc, together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation.
Featured Stories
- Five stocks we like better than Novanta
- Investing in Travel Stocks Benefits
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- What is a Low P/E Ratio and What Does it Tell Investors?
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.